Interleukin-15 in Kidney Disease and Therapeutics

Overview

Journal Curr Opin Nephrol Hypertens

Specialties Cardiology & Vascular Diseases
Nephrology

Date 2024 Jan 2

PMID 38164877

Authors

Gentzon Hall

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Interleukin 15 (IL-15) is a member of the IL-2 family of common gamma chain receptor cytokines with well described anti-inflammatory, pro-survival and pro-proliferative signaling properties. The cytoprotective role of IL-15 in the kidney is now coming into focus with recent reports of its beneficial actions in various forms of kidney disease. This review will summarize what is currently known about IL-15 signaling in the kidney and highlight recent evidence of its beneficial effects on kidney physiology.

Recent Findings: IL-15 and its heterotrimeric receptor are expressed throughout the kidney. Like all IL-2 family cytokines, IL-15 can activate signaling through the Janus Kinase (JAK)/Signal transducer of activated T-cells (STAT), phosphoinositol-3 kinase (PI-3K)/AKT and mitogen activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathways and recent evidence suggests that STAT5B is an essential transcriptional mediator of prosurvival signaling in glomerular visceral epithelial cells (i.e. podocytes). IL-15 has also been shown to suppress pro-apoptotic signaling in models of acute kidney injury and pro-fibrotic signaling in models of chronic kidney disease.

Summary: The cytoprotective properties of IL-15 suggest that it may have potential as a nonimmunosuppresive therapeutic for kidney disease. A novel class of IL-15 immunotherapies has emerged for the treatment cancer and some have demonstrated efficacy in clinical trials. These well tolerated IL-15 agonists could possibly be repurposed for the treatment of kidney disease and warrant further exploration.

References

Giron-Michel J, Azzi S, Khawam K, Mortier E, Caignard A, Devocelle A . Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway. PLoS One. 2012; 7(2):e31624. PMC: 3283658. DOI: 10.1371/journal.pone.0031624. View

Conlon K, Lugli E, Welles H, Rosenberg S, Tito Fojo A, Morris J . Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2014; 33(1):74-82. PMC: 4268254. DOI: 10.1200/JCO.2014.57.3329. View

Liu X, Liu Z, Wang C, Miao J, Zhou S, Ren Q . Kidney tubular epithelial cells control interstitial fibroblast fate by releasing TNFAIP8-encapsulated exosomes. Cell Death Dis. 2023; 14(10):672. PMC: 10570316. DOI: 10.1038/s41419-023-06209-w. View

Fehniger T, Caligiuri M . Interleukin 15: biology and relevance to human disease. Blood. 2001; 97(1):14-32. DOI: 10.1182/blood.v97.1.14. View

Devocelle A, Lecru L, Francois H, Desterke C, Gallerne C, Eid P . Inhibition of TGF-1 Signaling by IL-15: A Novel Role for IL-15 in the Control of Renal Epithelial-Mesenchymal Transition: IL-15 Counteracts TGF-1-Induced EMT in Renal Fibrosis. Int J Cell Biol. 2019; 2019:9151394. PMC: 6642769. DOI: 10.1155/2019/9151394. View

Yang H, Zuo Y, Fogo A . Models of chronic kidney disease. Drug Discov Today Dis Models. 2011; 7(1-2):13-19. PMC: 3030258. DOI: 10.1016/j.ddmod.2010.08.002. View

Stoklasek T, Schluns K, Lefrancois L . Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006; 177(9):6072-80. PMC: 2847275. DOI: 10.4049/jimmunol.177.9.6072. View

Carson W, Ross M, Baiocchi R, Marien M, Boiani N, Grabstein K . Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest. 1995; 96(6):2578-82. PMC: 185961. DOI: 10.1172/JCI118321. View

Genovese G, Friedman D, Ross M, Lecordier L, Uzureau P, Freedman B . Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010; 329(5993):841-5. PMC: 2980843. DOI: 10.1126/science.1193032. View

10.

Grabstein K, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V . Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994; 264(5161):965-8. DOI: 10.1126/science.8178155. View

11.

Gordy L, Bezbradica J, Flyak A, Spencer C, Dunkle A, Sun J . IL-15 regulates homeostasis and terminal maturation of NKT cells. J Immunol. 2011; 187(12):6335-45. PMC: 3237743. DOI: 10.4049/jimmunol.1003965. View

12.

Tilly G, Doan-Ngoc T, Yap M, Caristan A, Jacquemont L, Danger R . IL-15 Harnesses Pro-inflammatory Function of TEMRA CD8 in Kidney-Transplant Recipients. Front Immunol. 2017; 8:778. PMC: 5492498. DOI: 10.3389/fimmu.2017.00778. View

13.

Zhang L, Zhou F, Yu X, Zhu Y, Zhou Y, Liu J . C/EBPα deficiency in podocytes aggravates podocyte senescence and kidney injury in aging mice. Cell Death Dis. 2019; 10(10):684. PMC: 6746733. DOI: 10.1038/s41419-019-1933-2. View

14.

Yang J, Chang E, Cherry A, Bangs C, Oei Y, Bodnar A . Human endothelial cell life extension by telomerase expression. J Biol Chem. 1999; 274(37):26141-8. DOI: 10.1074/jbc.274.37.26141. View

15.

Budagian V, Bulanova E, Paus R, Bulfone-Paus S . IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006; 17(4):259-80. DOI: 10.1016/j.cytogfr.2006.05.001. View

16.

Kaverina N, Schweickart R, Chan G, Maggiore J, Eng D, Zeng Y . Inhibiting NLRP3 signaling in aging podocytes improves their life- and health-span. Aging (Albany NY). 2023; 15(14):6658-6689. PMC: 10415579. DOI: 10.18632/aging.204897. View

17.

Devocelle A, Lecru L, Ferlicot S, Bessede T, Candelier J, Giron-Michel J . IL-15 Prevents Renal Fibrosis by Inhibiting Collagen Synthesis: A New Pathway in Chronic Kidney Disease?. Int J Mol Sci. 2021; 22(21). PMC: 8583733. DOI: 10.3390/ijms222111698. View

18.

Floege J, Hackmann B, Kliem V, Kriz W, Alpers C, Johnson R . Age-related glomerulosclerosis and interstitial fibrosis in Milan normotensive rats: a podocyte disease. Kidney Int. 1997; 51(1):230-43. DOI: 10.1038/ki.1997.28. View

19.

Giri J, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S . Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994; 13(12):2822-30. PMC: 395163. DOI: 10.1002/j.1460-2075.1994.tb06576.x. View

20.

Armitage R, Macduff B, Eisenman J, Paxton R, Grabstein K . IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol. 1995; 154(2):483-90. View